VA
MRSN

VR Adviser’s Mersana Therapeutics MRSN Stock Holding History

VR Adviser’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-142,973
Closed -$1.23M – 35
2025
Q1 		$1.23M Sell
142,973
-267,339
-65% -$4.13M 0.1% 33
2024
Q4 		$14.7M Sell
410,312
-42,808
-9% -$2.21M 1.01% 23
2024
Q3 		$21.4M Hold
453,120
– – 1.12% 25
2024
Q2 		$22.8M Hold
453,120
– – 1.45% 22
2024
Q1 		$50.7M Hold
453,120
– – 2.41% 15
2023
Q4 		$26.3M Hold
453,120
– – 1.8% 18
2023
Q3 		$14.4M Buy
+453,120
New +$21.5M 1.51% 21
2020
Q2 		– Sell
-104,956
Closed -$15.3M – 20
2020
Q1 		$15.3M Buy
+104,956
New +$18.3M 4.14% 8

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

VR Adviser's MRSN Position: Q2 2025 in Review

VR Adviser sold out of Mersana Therapeutics (MRSN) in Q2 2025, closing a stake of 142,973 shares — an estimated $1.23M sold.

VR Adviser first reported a position in MRSN in Q1 2020 and held it in 8 quarters. The position peaked at $50.7M in Q1 2024. 83 funds tracked by Wall St. Rank hold MRSN as of Q2 2025.

  • VR Adviser reported no remaining Mersana Therapeutics position as of Q2 2025 after selling out during the quarter.
  • VR Adviser sold 142,973 Mersana Therapeutics shares in Q2 2025, an estimated $1.23M.
  • VR Adviser first reported a position in Mersana Therapeutics in Q1 2020 and held it in 8 quarters.
  • VR Adviser's Mersana Therapeutics position peaked at $50.7M in Q1 2024.
  • 83 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q2 2025.

Based on VR Adviser's 13F filing for Q2 2025, filed 14 Aug 2025.